Skip to main content
OpenTrials
Completed

NCT Number: NCT03080493

Gabapentin for Pain Control After Osmotic Dilator Insertion and Prior to D&E Procedure: a Randomized Controlled Trial

Women having abortion procedures between 15 weeks 0 days and 23 weeks 6 days gestational age on the day of their procedure commonly have dilators placed in their cervix overnight before the abortion procedure. The dilators are put in during a pelvic exam in the clinic and after women go home they expand slowly overnight to open the cervix before the abortion procedure the next day. This can be a painful experience and health care providers often give women different kinds of pain medicine to help them.

The investigators are interested in whether a medicine called gabapentin, which is a non-narcotic medicine, could help. Gabapentin is approved by the U.S. Food and Drug Administration (FDA) for prevention of seizures and for treating nerve pain and doctors are also using it to decrease pain for people having surgical procedures.

The main goals of our study are to learn about:

1. Women's pain experience with dilators in their cervix overnight before the abortion procedure 2. How well gabapentin works to decrease women's pain while they have the dilators in their cervix

Women who enroll in the study will get a dose of either gabapentin or placebo (a pill with no medicine in it) before their dilators are placed in the clinic. The medication they get (gabapentin or placebo) will be chosen by chance, like flipping a coin. Neither the women in the study nor the doctors giving them the medication will know which medication they receive so the investigators can learn about their pain without being influenced by knowing which medication they take. Doctors will be able to find out which medication women got if there is an emergency or if it changes their medical care.

The investigators will communicate with women in real time overnight by text messaging to see how much pain they are having in the moment and how much pain medicine they are taking.

The investigators hypothesize that women who receive gabapentin will have a smaller increase in their pain with the dilators than women who receive placebo (a pill with no medicine in it).

The investigators' findings will help doctors understand women's pain experience with dilators better and possibly provide a new way of treating pain with gabapentin.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Abortion, Induced Cervical Preparation Neurologic Manifestations Pain Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Phase 4

Primary location

University of California Davis Health System

Sacramento, California, 95817, United States

About this study

The investigators have planned a double-blind randomized controlled trial of repeated doses of gabapentin compared to placebo for pain management during the time after dilator insertion and prior to D&E the subsequent day.

  • Participants will receive gabapentin 600 mg or placebo prior to dilator insertion
  • Pain scores will be measured via numeric rating scale (NRS) at baseline and 5 minutes after last dilator insertion while the participant is in clinic
  • Additional pain scores, side effects (specifically dizziness and sedation), and additional analgesic use will be obtained by text message while the patient is home at 2 hours, 4 hours, and 8 hours after time of dilator insertion
  • Subjects will take a second dose of study drug (either gabapentin 600 mg or placebo, concordant with their initial medication) at 8 hours after their first dose
  • Final pain score, side effect, and analgesic use assessment will occur upon presentation to the pre-operative are for D&E the subsequent day

There will be no change in standard insertion of osmotic dilators (hygroscopic dilators only with Lidocaine 20mL cervical anesthesia), or provision of home analgesic medications (ibuprofen and acetaminophen with codeine in our practice).

The investigators hypothesize that women who receive gabapentin will report a smaller increase in pain from baseline at 8 hours after dilator placement compared to women receiving placebo.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 15 weeks 0 days gestational age - 23 weeks 5 days gestational age at time of dilator insertion
  • Able to read and write in English
  • Active cell phone with text messaging capability
  • Ride home from dilator insertion clinic appointment

Exclusion criteria

  • Current use of gabapentin or pregabalin
  • Allergy to gabapentin, acetaminophen, codeine, or ibuprofen
  • Self reported renal disease (severe impaired renal function)
  • Self reported current or chronic narcotic use (typical daily use)
  • Women with any issue that, in the opinion of the investigator, would interfere with study participation or generating accurate study data

Treatment and study plan

Gabapentin 600mg

Drug

Gabapentin 600 mg PO (two total doses, thereby lasting duration while osmotic dilators are in place)

Other names: Neurontin

Placebo oral capsule

Drug

Packaged identical to gabapentin dosing

Other names: Carboxymethyl cellulose

acetaminophen/codeine and ibuprofen

Drug

Over the counter analgesic medications

Other names: Tylenol-Codeine No. 3, Advil

Primary outcomes

  1. Mean Change From Baseline in NRS Pain Score at 8 Hours After Dilator Insertion

    Time frame: 8 hours after insertion of last osmotic dilator

    Pain score based on numeric rating scale (NRS [0 lowest value to 10 highest value, in which 0 is the lowest amount of pain and 10 is the highest amount of pain]); Baseline obtained prior to study drug ingestion/dilator insertion. NRS pain score obtained via text message.

Secondary outcomes

  1. Mean Change From Baseline in NRS Pain Score at 5 Minutes After Last Dilator Insertion

    Time frame: 5 minutes after insertion of last osmotic dilator

    Pain score based on numeric rating scale (NRS [0 lowest value to 10 highest value, in which 0 is the lowest amount of pain and 10 is the highest amount of pain]); Baseline obtained prior to study drug ingestion/dilator insertion. NRS pain score obtained in person before subject leaves clinic appointment.

  2. Mean Change From Baseline in NRS Pain Score at 2 Hours After Dilator Insertion

    Time frame: 2 hours after insertion of last osmotic dilator

    Pain score based on numeric rating scale (NRS [0 lowest value to 10 highest value, in which 0 is the lowest amount of pain and 10 is the highest amount of pain]); Baseline obtained prior to study drug ingestion/dilator insertion. NRS pain score obtained via text message.

  3. Mean Change From Baseline in NRS Pain Score at 4 Hours After Dilator Insertion

    Time frame: 4 hours after insertion of last osmotic dilator

    Pain score based on numeric rating scale (NRS [0 lowest value to 10 highest value, in which 0 is the lowest amount of pain and 10 is the highest amount of pain]); Baseline obtained prior to study drug ingestion/dilator insertion. NRS pain score obtained via text message.

  4. Mean Change From Baseline in NRS Pain Score at Time of Presentation for D&E Procedure (Day Following Dilator Insertion)

    Time frame: Time of presentation for D&E (day after dilator insertion)

    Pain score based on numeric rating scale (NRS [0 lowest value to 10 highest value, in which 0 is the lowest amount of pain and 10 is the highest amount of pain]); Baseline obtained prior to study drug ingestion/dilator insertion. NRS pain score obtained in person upon presentation for D&E procedure.

  5. Number of Participants Using Narcotic Pain Medication (Acetaminophen/Codeine)

    Time frame: Collected between each subject contact (2 hours, 4 hours, 8 hours after dilator insertion and at time of presentation for D&E procedure)

    Subject account of how many used acetaminophen/codeine (standard medications given for supplement NSAID as needed after dilator insertion)

Sponsors and collaborators

Lead sponsor

University of California, Davis

Other

Collaborators

  • Society of Family Planning

Registry information

Acronym: GABA

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Mar 15, 2017
Registry last updated
Apr 14, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.